Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pharma plays chicken with U.K. prices
Last month, the Brits ripped up their pharmaceuticals pricing agreement and demanded to renegotiate. This month, Big Pharma strikes back. The Association of the British Pharmaceutical Industry claims that changes in the pricing scheme will cause big layoffs among drugmakers. And an industry poll showed that drugmakers expect U.K. conditions to deteriorate (83 percent) and that they plan to cut R&D investment, reduce spending on buildings and equipment, cut the number of clinical trials in the U.K., and reduce their level of manufacturing. Really. They will. Unless the government pays, they promise they absolutely will.
Of course the ABPI admits that Big Pharma already is in the midst of layoffs. Should we remind them that outsourcing and plant closures were already in the works, too?
- read the Telegraph article
- see the survey at Pharmalot
- get more in Forbes
Related Articles:
Pact adds cost effectiveness to drug study. Report
U.K. aims to slice drug prices 10%. Report
U.K. accepts J&J's money-back guarantee. Report
NHS fights expensive Alzheimer's drugs. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


